Tenzai

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

Arato.ai is an advanced AI agent simulation platform that helps organizations test, evaluate, and monitor generative LLM applications for production readiness. The system autonomously generates dynamic, real world user scenarios to execute thousands of multi turn conversations against AI agents to identify hallucinations, security threats, and UX drifts.

Eco Wave Power is the global innovator and creator of unique wave energy devices, owning and developing their patented technology. They design, produce, and operate wave energy converters and are poised to become a leader in the industry. They are the only company to win the Frost & Sullivan Product Innovation Award for their effective energy harvesting solutions.

Pulsenmore is the emerging leader in connected at-home ultrasound, delivering convenience and efficiency beyond traditional in-facility imaging. Our unique handheld ultrasound scanner docks with the patient’s smartphone to deliver high quality images that can be created anywhere, stored and forwarded for clinical review or shared in an online consultation. Founded in 2015, Pulsenmore is based in Omer, Israel and is privately held.

Kinoa provides an AI-powered LiveOps platform that helps mobile app and game companies manage user engagement, retention, and monetization. The platform lets teams design behavior-driven user journeys that respond to milestones, purchases, and inactivity in real time. It includes tools for in-app dynamic content, in-app messages, push notifications, remote configuration, feature settings, and webhooks, all managed from a single dashboard. Kinoa supports live user state management and live segments so experiences, offers, and pricing can be personalized instantly as behavior changes. It also offers calendar, resource management, and A/B testing capabilities to plan campaigns, manage in-app items and currencies, and optimize configurations. Integration is done via SDKs or APIs, after which operations teams can run experiments and updates without ongoing developer involvement.

Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and improve bone formation and enable shorter and more successful healing of bone and soft tissue in events such as a fracture or dental implant. Magdent’s solutions are high usability medical devices that incorporate a battery, electronic modules, and a coil. The orthopedic device is a thin lightweight silicon patch, placed over the fracture either under the case or over the skin while the dental device is shaped like a healing abutment.

Brevel has created an innovative method of cultivating microalgae that is both sustainable and cost-effective, while also producing high-quality output for a range of markets that have yet to be explored. This technology utilizes advanced indoor systems that are sterile and fully automated, with intense internal illumination. As a result, Brevel has achieved remarkable results, including a cost reduction of over 90% and yields that are up to 200 times higher than existing alternatives. Leveraging these production capabilities, Brevel is now venturing into various markets that require products derived from microalgae.

InterCure is a manufacturer and distributor of pharmaceutical medical cannabis products.

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Dream Security is a cybersecurity firm that creates artificial intelligence products to safeguard against online dangers. They offer a range of cybersecurity services such as AI-powered threat detection, incident response teams, vulnerability management, security awareness training, compliance and risk management assistance, cloud security solutions, and consulting services for developing cybersecurity strategies.

NextVision Stabilized Systems is a technology manufacturing company that focuses on electro-optical imaging systems. It designs and produces stabilized EO/IR cameras, vision payloads, accessories, and related software applications, and provides system integration and support services for surveillance, inspection, monitoring, and industrial mission use cases.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.